fruquintinib,regorafenib
hutchmed,bayer
['fruquintinib', ' rego ', 'fresco-2']
from re: phase iii fresco-2 trial: "fruquintinib increased os vs placebo for those who received standard of care, which suggests that it actually may be best if we move forward." median os &amp; mpfs were significantly better than the prior rego +/- tas-102 studies. 
We FIGHT to cure #colorectalcancer and serve as #RelentlessChampions of hope for all affected by this disease! ????